Novadip announced implantation of the first two patients in its Phase 3 pivotal trial of NVD003 for Congenital Pseudarthrosis of the Tibia.
Novadip is advancing the standard of care in bone and tissue regenerative medicine, focusing on developing a new class of regenerative tissue products that accelerate healing of large bone defects, bone non-union, and spine fusion in a single treatment
Novadip is advancing the standard of care in bone and tissue regenerative medicine, focusing on developing a new class of regenerative tissue products that accelerate healing of large bone defects, bone non-union, and spine fusion in a single treatment.